{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=25", "query": { "condition": "LCC", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 1039, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T05:54:38.234Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00019513", "title": "Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer", "Lung Cancer", "Lymphoma", "Pancreatic Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "1998-08", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-23", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019513" }, { "nct_id": "NCT00532441", "title": "Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gabi Chiorean, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2007-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2016-02-12", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 12, "location_summary": "Newark, Delaware • Chicago, Illinois • Bloomington, Indiana + 6 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00532441" }, { "nct_id": "NCT05038254", "title": "Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Metastatic Colon Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Small Intestinal Neoplasm", "Metastatic Malignant Thoracic Neoplasm", "Metastatic Pancreatic Carcinoma", "Metastatic Rectal Carcinoma", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2021-05-12", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038254" }, { "nct_id": "NCT01899261", "title": "Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Hepatocellular Carcinoma", "Advanced Adult Hepatocellular Carcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Recurrent Adult Liver Carcinoma" ], "interventions": [ { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2010-10-07", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01899261" }, { "nct_id": "NCT03778957", "title": "A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Transarterial Chemoembolization (TACE)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 724, "start_date": "2018-11-30", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 24, "location_summary": "Costa Mesa, California • La Jolla, California • Orange, California + 19 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03778957" }, { "nct_id": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Estrogen Receptor-negative Breast Cancer", "Extensive Stage Small Cell Lung Cancer", "Gastrointestinal Stromal Tumor", "HER2-negative Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Triple-negative Breast Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031681" }, { "nct_id": "NCT00524316", "title": "Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "hepatic artery embolization", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 16, "start_date": "2007-04", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524316" }, { "nct_id": "NCT03739164", "title": "Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Liver Cancer", "Liver Tumor", "Hepatocellular Carcinoma", "Hilar Cholangiocarcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Florida Hospital Tampa Bay Division", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 10, "start_date": "2018-07-18", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2018-11-13", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739164" }, { "nct_id": "NCT03267524", "title": "Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Liver Carcinoma", "Caregiver", "Colorectal Carcinoma", "Lung Carcinoma", "Malignant Digestive System Neoplasm", "Pancreatic Carcinoma" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 87, "start_date": "2017-11-09", "completion_date": "2025-03-14", "has_results": false, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03267524" }, { "nct_id": "NCT00827177", "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Treatment with ARQ 197 in combination with sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2009-09", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2014-01-24", "last_synced_at": "2026-10-24T05:54:38.234Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Buffalo, New York • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00827177" } ] }